OPTN OptiNose Inc.

6.35
+0.33  (+5%)
Previous Close 6.02
Open 6.1
Price To Book 3.85
Market Cap 263,118,079
Shares 41,435,918
Volume 374,679
Short Ratio
Av. Daily Volume 246,402

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 commencement of enrolment announced December 10, 2018.
XHANCE
Chronic sinusitis
Approval announced September 18, 2017 (prior to IPO).
XHANCE
Nasal polyps
Commencement of enrolment announced December 10, 2018.
XHANCE
Nasal polyps - pediatric

Latest News

  1. OptiNose's Q2 Results Reflect Strong Underlying Trends, RBC Says
  2. OptiNose, Inc. (OPTN) Q2 2019 Earnings Call Transcript
  3. OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
  4. Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
  5. OptiNose, Inc. to Host Earnings Call
  6. Analysts Estimate OptiNose (OPTN) to Report a Decline in Earnings: What to Look Out for
  7. Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019
  8. Those Who Purchased OptiNose (NASDAQ:OPTN) Shares A Year Ago Have A 73% Loss To Show For It
  9. Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
  10. Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal
  11. You Can Get Buy Signals From Short Selling
  12. OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
  13. OptiNose: 1Q Earnings Snapshot
  14. Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights
  15. OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  16. Have Insiders Been Buying OptiNose, Inc. (NASDAQ:OPTN) Shares?
  17. Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019
  18. OptiNose Analysts Projects Prescription Growth In 2019, Beyond
  19. OptiNose, Inc. (OPTN) Q4 2018 Earnings Conference Call Transcript